Interview with Dejan Jovanovic, General manager, Astellas Russia
When our team interviewed Amit Makwana at Astellas’ European Headquarters in the UK, he noted that the Russian affiliate is experiencing a huge growth rate that is very difficult for…
Address: 109147, Moscow,Russia
Tel: +7 (495) 737 0755
Web: http://www.astellas.com/worldwide.html
Pharma (the Netherlands), its Representative office was opened in Moscow in 1994. Yamanouchi Company was found on the basis of Brocades Company. In 2005 a new multinational company Astellas was found as a result of two Japanese companies’ merger – Fujisawa and Yamanouchi. Main Astellas goal is to improve people’s lives and give them hope for the future with innovative pharmaceutical products and also become a Global Category Leader in chosen therapy areas.
Astellas is among top 20 companies of the world successfully managing its business in different countries such as Japan, North America (the USA and Canada), Europe and Asia. Headcount of Astellas worldwide is more than 17 thousand people.
Russian affiliate is related to European branch – Astellas Pharma Europe. Astellas Russia is responsible for business in Russia, the Ukraine, Belarus, Kazakhstan, Azerbaijan, Armenia, Moldova, Georgia, Kirgizia, Turkmenistan, Tajikistan, Uzbekistan and Mongolia.
Astellas has 4 global corporate principals which are called STAR: Success driven, Team oriented, Adoptable and Respectful.
Russian affiliate headcount is continuingly growing. They are young and vigorous professionals who can achieve their ambitious goals. Astellas aim is to become an Employer of Choice. That is why it is trying to improve HR policy, social package and team spirit.
Infectives, Transplantation, Oncology, Pail Management and others. Astellas brand products are: Omnic, Prograf, Flemoxin Solutab, Wilprafen Solutab, Unidox Solutab, Pimafucin, Zineryt, DeNol, Phosphalugel and others.
When our team interviewed Amit Makwana at Astellas’ European Headquarters in the UK, he noted that the Russian affiliate is experiencing a huge growth rate that is very difficult for…
You founded Euroservice, and have managed this business since its inception in 1996. What are the key drivers that have facilitated the growth of this company from a staff of…
In spring of 2010, Protek became the first Russian wholesaler to enter the public stock market, raising $400Mn in the biggest Russian IPO since 2007. You offered the IPO directly…
PAREXEL prides itself on improving the time schedule of a product launch. What is the significance of time-to-market in the healthcare industry, and how can PAREXEL expedite the process better…
Since our last report on Russia in 2007, there has been much emphasis placed on developing local industry, and reducing the nation’s reliance on imported pharmaceutical products. How do you…
You worked for ten years at Schering-Plough—one of the largest pharmaceutical companies in the world. In February of last year, you joined Merz Pharma, a much smaller player. Some may…
You have been at your current position for less than a year, and joined BIOCODEX after having managed the Russian affiliate of Yves Saint Laurent. You have a long history…
Russia and India have recently held a number of discussions regarding increased cooperation within the pharmaceutical sector. For example, the two nation’s health ministers have discussed decreasing administrative barriers to…
Biofund is an independent spin-off of the broader Russian Venture Capital organization. What is the working relationship and synergy between these agencies, and what are the market conditions that have…
Petrovax has always been an innovative company, making it quite unique in Russia where the domestic industry is predominantly comprised of generics manufacturers. How would you describe the positioning of…
After a long history in Philips, this is your first tenure as a regional CEO. Having been at this position for less than a year, what are your impressions of…
You were a Russian manager from 1996-2004, departed to Germany for some time, and recently made your way back to Russia in 2010. How has Russian healthcare and industry changed,…
You were responsible for merging Pierre Fabre’s activities in Russia in 2008, and heading the new legal entity and 100% subsidiary. What is it like to set up a new…
See our Cookie Privacy Policy Here